猪脾提取的转移因子(Transfer Factor,TF)在国内已进行了一些实验室和临床研究,并与人脾转移因子进行了比较,认为其生化组分及生物活性基本相同,在临床上它对若干免疫缺陷,免疫失衡(包括各种变态反应),某些感染(包括真菌、病毒)及肿瘤的治疗均获得较好疗效,但目前尚未见任何毒性试验报告。基于上述情况,我们对南京生化制药厂试制的猪脾转移因子进行了初步的临床前药理试验(包括急性、亚慢性毒性测验、微核试验),现报告如下 Transfer factor (TF) extracted from porcine spleen has been studied in laboratory and clinical studies in China. Compared with human spleen transfer factor, it is considered that biochemical components and biological activity are basically the same. In clinical practice, Several immunodeficiencies, immune imbalances (including various allergies), certain infections (including fungi, viruses) and tumors have yielded good results, but no toxicities reports have been reported so far. Based on the above, we conducted a preliminary preclinical pharmacological test (including acute, sub-chronic toxicity test, micronucleus test) of pig spleen transfer factor trial produced by Nanjing Biochemical Pharmaceutical Factory, which is reported as follows